Therapeutics News and Research

RSS
Voluntis closes €20.75 million ($29 million) Series D financing round

Voluntis closes €20.75 million ($29 million) Series D financing round

UTMB awarded $6.6 million grant to establish Translational Addiction Sciences Center

UTMB awarded $6.6 million grant to establish Translational Addiction Sciences Center

Discovery offers potential target for reversing progression of end-stage liver disease

Discovery offers potential target for reversing progression of end-stage liver disease

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Variant of cell surface protein may help develop drugs for gastric cancer

Variant of cell surface protein may help develop drugs for gastric cancer

Initial treatment for brain infection caused by fungus could be treated in 3 days, say Liverpool scientists

Initial treatment for brain infection caused by fungus could be treated in 3 days, say Liverpool scientists

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

Scientists develop DNA nanodevices that survive body's immune defenses

Scientists develop DNA nanodevices that survive body's immune defenses

Vaccine against H. pylori infection is within reach

Vaccine against H. pylori infection is within reach

New data-based model accurately estimates hemoglobin A1c using SMBG readings

New data-based model accurately estimates hemoglobin A1c using SMBG readings

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Researchers uncover novel function of Amyloid Precursor Protein linked to Alzheimer's disease

Researchers uncover novel function of Amyloid Precursor Protein linked to Alzheimer's disease

New genetic evidence strengthens link between role of dietary fats with colon cancer progression

New genetic evidence strengthens link between role of dietary fats with colon cancer progression

Study points to new therapeutic strategy for treating depression

Study points to new therapeutic strategy for treating depression

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.